Perrigo

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Perrigo reports strong Q1 growth, faces challenges in product shortages

Perrigo's Q1 2023 performance showcased growth and margin expansion, with a focus on operational excellence. The company faces challenges with product shortages and declining national brand volumes but sees opportunities in pricing increases and supply chain optimization. By leveraging strengths in private label growth and strategic initiatives, Perrigo aims to deliver on guidance for the year.

Perrigo reports strong Q2 performance, eyes Opill launch success

Perrigo's Q2 2023 earnings call highlighted strong financial performance, strategic strengths, key challenges, and growth opportunities. The company is focused on sustainable growth, market differentiation, and leveraging its capabilities for success in the industry.

Perrigo reports solid Q3 earnings, navigates challenges for future growth

Perrigo's Q3 performance showcased growth in net sales and margin expansion, despite challenges in certain product segments. The company remains focused on margin improvement, supply chain optimization, and growth initiatives for future success. With revised outlooks and ongoing strategic efforts, Perrigo aims to navigate challenges and capitalize on growth opportunities.

Perrigo reports robust Q4 earnings, focuses on growth initiatives

Perrigo's Q4 2023 earnings call showcased strong financial performance, with notable growth in net sales and margins.
While facing challenges in its infant formula business, the company outlined remediation plans and expects recovery in the second half of 2024.
Opportunities lie in the launch of Opill, Project Energise, and a focus on strengthening the infant formula business.
Perrigo aims to drive growth by executing strategic initiatives and providing more clarity on growth perspectives during an upcoming Investor Day.

Perrigo reports Q1 challenges, Opill success, and growth opportunities

Perrigo faced challenges in net sales due to infant formula actions but showed strength in innovation and store brands.
Opportunities lie in adapting to retailer inventory changes and expected gross margin improvement in Q2.
The company remains on track to meet 2024 commitments with progress in infant formula recovery and successful product launches.
Analysts focused on infant formula progress, Opill revenue potential, and portfolio refinements during the call.

Perrigo reports Q2 resilience amidst challenges, eyes growth opportunities

Perrigo faced challenges in Q2 2024 with a decline in organic net sales, primarily due to infant formula and certain category sales. Despite this, the company showed resilience with growth in operating income and a focus on core segments. Opportunities lie in recovering share, enhancing marketing, and the potential for infant formula recovery.

Perrigo reports robust Q3 earnings, focuses on efficiency and growth

Perrigo's Q3 performance reflects a resilient financial position, marked by strong EPS growth and operational efficiency gains through cost-saving initiatives.
While facing challenges in net sales decline, the company's strategic focus on core business stabilization and efficiency improvements bodes well for long-term growth.
With a commitment to financial targets, Perrigo is poised to capitalize on opportunities for revenue diversification and market expansion, supported by a strengthened operational foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Perrigo (PRGO) offers to acquire HRA Pharma with several leading OTC brands in its portfolio for almost $2.1 billion. The acquisition will complete Perrigo's transformation into a leading self-care company.

Perrigo (PRGO) to Acquire Another Self-Care Company HRA Pharma

Perrigo Company plc (PRGO) CEO Murray Kessler on HRA Pharma Acquisition - Conference Call Transcript

In a statement, Perrigo Company PLC (NYSE: PRGO) announced that it had inked a deal, and the company is set to acquire Héra SAS. The acquisition will make Perrigo the world leader in the consumer self-care segment.

Perrigo will take over HRA Pharma, making it the world leader in consumer self-care

Perrigo has agreed to buy consumer self-care company HRA Pharma in a deal worth around $2.1 billion in cash, sending the stock higher in early trading.

Perrigo to Buy Consumer Self-Care Company HRA Pharma in $2.1 Billion Deal

Perrigo Company plc (NYSE: PRGO) will acquire HRA Pharma, a consumer self-care company, from Astorg and Goldman Sachs Asset Management. The transaction is valued at €1.8 billion, or approximately $2.1 billion in cash.

Perrigo Buys Consumer Self-Care Firm For $2.1B: Highlights

Perrigo Co. Plc PRGO, -0.60% said Wednesday it has signed a binding offer to acquire Héra SAS, or HRA, a global self-care company, from funds affiliated with private-equity firm Astorg and Goldman Sachs Asset Management for about $2.1 billion in cash. HRA is an over-the-counter products company with with three self-care brands in blister care with Compeed, in women's health with ellaOne and in scar care with Mederma.

Perrigo to acquire consumer self-care company HRA Pharma for about $2.1 billion in cash

DUBLIN, Sept. 8, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) ("Perrigo" or the "Company") today announced that it has signed a binding offer to acquire Héra SAS ("HRA" or "HRA Pharma"), a leading global consumer self-care company, from funds affiliated with private equity firm Astorg and Goldman Sachs Asset Management.

Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma

Brown & Brown

Ceridian HCM Holding Inc.

S&P Global

Team

Unum

NEW YORK, Sept. 3, 2021 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 to ensure each index is more representative of its market capitalization range.

Match Group, Ceridian HCM and Brown & Brown Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

DUBLIN, Sept. 3, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that Perrigo President and CEO, Murray S.

Perrigo To Host Virtual Investor Meetings At The 2021 Barclays Global Consumer Staples Conference

We believe that Perrigo stock, a healthcare company that provides over-the-counter self-care products, looks like a good buying opportunity at the present time. PRGO stock trades near $41 currently and it is, in fact, down 33% from its pre-Covid high of around $61 in February 2020 – before the.

Here's Why Perrigo Stock May See Higher Levels In The Near Term

LyondellBasell Industries

Triton International

Deep value dividend stocks aren't just cheap; they have high yields and higher growth potential, making a potent mix for any investor's portfolio. The post 3 Undervalued Dividend Stocks to Buy For High Total Returns appeared first on InvestorPlace.

3 Undervalued Dividend Stocks to Buy For High Total Returns

Analysts cooled on the company's prospects following its latest earnings report.

Why Perrigo Stock Tumbled 16% This Week

The price of Perrigo stock, a healthcare company that provides over-the-counter self-care products, has seen a 10% fall over the last five trading days, and much of this fall has come in yesterday's trading session (Aug 11), following the company's Q2 release. The company reported revenues.

Will Perrigo Stock Rebound After A 12% Fall Yesterday?

A disappointing earnings report pushed down shares of the over-the-counter medicine seller.

Why Perrigo Stock Was Slipping Today

Perrigo Company plc (NYSE: PRGO) has posted Q2 sales of $981 million, an increase of 3.4% Y/Y, missing the consensus of $1.02 billion. The sales growth was primarily due to an increase in most businesses and favorable currency movements, partially offset by Y/Y customer inventory reductions and a historically weak cough/cold season.

Perrigo Q2 Stock Plunges After Q2 Earnings Miss, Weak Cough/Cold Season

Perrigo Company plc (PRGO) CEO Murray Kessler on Q2 2021 Results - Earnings Call Transcript

Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.

Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season

Perrigo stock slid after the consumer healthcare firm said it swung to a loss in the latest quarter, largely because of a weak cold and cough season.

Perrigo Stock Slides Because Fewer People Got Colds This Year

Perrigo Co plc (NYSE: PRGO) said on Wednesday it concluded its fiscal second quarter in loss. The NYSE-listed shares of the company were down more than 10% this morning on weak guidance for the future.

Here's why Perrigo shares are down more than 10% on Wednesday

Perrigo (PRGO) delivered earnings and revenue surprises of -18.03% and -3.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Q2 Earnings and Revenues Lag Estimates

Perrigo Co. Plc shares PRGO, +1.24% slid 6% in premarket trade Wednesday, after the Dublin, Ireland-based consumer self-care company swung to a loss for the second quarter and lagged consensus estimates. The company swung to a loss of $112 million, or 84 cents a share, in the quarter, after income of $12 million, or 9 cents a share, in the year-earlier period.

Perrigo shares slide 6% premarket as earnings fall short of estimates

DUBLIN, Aug. 11, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Consumer Self-Care Products, today announced financial results from continuing operations for the second quarter of fiscal year 2021 ended July 3, 2021. The Consumer Self-Care Americas ("CSCA") segment, the Consumer Self-Care International ("CSCI") segment and Corporate are included in results from continuing operations.

Perrigo Reports Second Quarter 2021 Financial Results From Continuing Operations

AppFolio

Cardinal Health

Citrix Systems

Ionis Pharma

PG&E

Splunk

In a churning market like this, you want to steer clear of stocks that are floundering. Here are sevens stocks to avoid today.

7 F-Rated Stocks to Avoid for the Rest of 2021

DUBLIN, July 28, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its second quarter 2021 financial results on Wednesday, August 11, 2021. The Company will also host a conference call beginning at 8:00 A.M.

Perrigo To Release Second Quarter 2021 Financial Results On August 11, 2021

DUBLIN, July 6, 2021 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Consumer Self-Care Products, announced today that it has completed the previously announced sale of its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for $1.55 billion, with customary adjustments, completing Perrigo's transformation to a global consumer self-care company. Perrigo CEO and President Murray S.

News for Perrigo Stock (PRGO)